ARQT Arcutis Biotherapeutics Inc

Price (delayed)

$21.32

Market cap

$1.1B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.68

Enterprise value

$1.1B

Arcutis Biotherapeutics, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent ...

Highlights
Arcutis Biotherapeutics's quick ratio has shrunk by 64% YoY and by 10% QoQ
Arcutis Biotherapeutics's net income has shrunk by 63% YoY and by 14% QoQ

Key stats

What are the main financial stats of ARQT
Market
Shares outstanding
51.42M
Market cap
$1.1B
Enterprise value
$1.1B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.23
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$232.8M
EBITDA
-$231.99M
Free cash flow
-$185.96M
Per share
EPS
-$4.68
Free cash flow per share
-$3.68
Book value per share
$5.04
Revenue per share
$0
TBVPS
$7.21
Balance sheet
Total assets
$364.11M
Total liabilities
$110.34M
Debt
$77.86M
Equity
$253.77M
Working capital
$325.96M
Liquidity
Debt to equity
0.31
Current ratio
10.89
Quick ratio
10.46
Net debt/EBITDA
-0.03
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-58.9%
Return on equity
-70.6%
Return on invested capital
-69.2%
Return on capital employed
-70.3%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARQT stock price

How has the Arcutis Biotherapeutics stock price performed over time
Intraday
-3.22%
1 week
-3.09%
1 month
1.57%
1 year
-17.46%
YTD
2.8%
QTD
10.7%

Financial performance

How have Arcutis Biotherapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$233.07M
Net income
-$234.64M
Gross margin
N/A
Net margin
N/A
Arcutis Biotherapeutics's net income has shrunk by 63% YoY and by 14% QoQ
The company's operating income has shrunk by 62% YoY and by 13% QoQ

Growth

What is Arcutis Biotherapeutics's growth rate over time

Valuation

What is Arcutis Biotherapeutics stock price valuation
P/E
N/A
P/B
4.23
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ARQT's EPS is down by 36% YoY and by 12% QoQ
Arcutis Biotherapeutics's equity has decreased by 44% YoY and by 15% QoQ
The stock's price to book (P/B) is 25% more than its last 4 quarters average of 3.5

Efficiency

How efficient is Arcutis Biotherapeutics business performance
The ROE has contracted by 36% YoY and by 30% from the previous quarter
The company's return on invested capital rose by 32% YoY
ARQT's return on assets is down by 23% year-on-year and by 21% since the previous quarter

Dividends

What is ARQT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARQT.

Financial health

How did Arcutis Biotherapeutics financials performed over time
Arcutis Biotherapeutics's quick ratio has shrunk by 64% YoY and by 10% QoQ
The current ratio has plunged by 64% YoY and by 10% from the previous quarter
Arcutis Biotherapeutics's debt is 69% lower than its equity
Arcutis Biotherapeutics's equity has decreased by 44% YoY and by 15% QoQ
ARQT's debt to equity is up by 19% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.